EN AR

Drugmakers Push Back on Anthropic CEO’s Decade Cancer Pledge

Nicole Jeffrey

Key Points

  1. Amodei repeated ahead of Anthropic's IPO that AI could end cancer and Alzheimer's within a decade.
  2. Eli Lilly's CEO and an AI drug-discovery founder say biology and clinical trials resist that compression.
  3. Anthropic carries a $1.3 trillion valuation partly built on the promise of transforming entire industries.

The latest:

Anthropic chief executive Dario Amodei repeated ahead of this week’s initial public offering that artificial intelligence could render cancer and Alzheimer’s relics of the past within a decade, according to The Wall Street Journal. Drug industry figures publicly disputed the timeline. The company’s $1.3 trillion valuation rests in part on the prospect of transforming enormous industries rather than selling a better chatbot.

Details:

  • The pledge: Amodei doubled down on the view that AI could make diseases such as cancer and Alzheimer’s things of the past within ten years, The Wall Street Journal reported. The claim arrived days before Anthropic’s listing, and the publication tied it directly to the valuation the company seeks from public investors.
  • The Lilly rebuttal: Eli Lilly chief executive Dave Ricks responded on X that such an outcome would be amazing but is not likely, according to the report. He argued the map of biology remains largely a blank page and described randomized human proof as the long pole in the tent.
  • Where AI helps: The report acknowledged AI can speed up parts of drug development, including scouring research, designing molecules and analyzing experiments. The gap is between finding a promising molecule and proving it safe and effective in people, which still requires clinical trials that run for years.
  • The data problem: Daphne Koller, the Stanford computer scientist who founded AI drug-discovery company insitro, argued in an August essay that because scientists understand so little about the biology of most diseases, the technology “will mostly help us generate failures faster.” She described herself as a believer in the technology.
  • The time limit: Koller said technologists are used to exponential growth in digital goods, where things appear infinitely compressible, but the real world compresses only so far. An Alzheimer’s trial must wait years to see whether cognitive decline has slowed, with a finite number of patients and trial sites.
  • Anthropic’s own bet: The company acquired Mithril Medicine, a biotech with a single employee whose founder used Claude to analyze data, plan experiments and coordinate outside labs on a treatment for a rare form of childhood muscular dystrophy. Anthropic’s wager is that the model can be replicated across many projects at once.
  • The timeline: Even if early results hold up, the Mithril program will not enter human trials until 2028, according to the report. Roughly nine in ten drugs that reach clinical trials fail to win approval, and a success could take years more before reaching patients.
  • The filing language: Anthropic’s IPO filing promotes AI’s potential to compress decades of scientific progress into years while warning that drug candidates face lengthy, costly and uncertain development and may never generate revenue. The company did not disclose how many such programs it intends to run.

Background:

Amodei is known in Silicon Valley as the AI executive who worries too much about the technology’s risks. In biotech, The Wall Street Journal reported, he is viewed as the one who worries too little about the obstacles between a computational discovery and an approved medicine.

Between the lines:

The dispute is less about whether AI works than about which part of drug development it touches. The capabilities cited by the report sit upstream, in research and molecule design, while the constraints cited by Ricks and Koller sit downstream, in trials bounded by patient cognition, site availability and a failure rate near 90%. The Journal argued investors should watch the distance between technological possibility and commercial reality.

What’s next

Anthropic’s listing this week is the first test of whether investors price the biology promise into the $1.3 trillion valuation. The Mithril muscular dystrophy program is not due to enter human trials before 2028.

What to read next